Literature DB >> 2218420

Ofloxacin in urinary tract infections.

B Kromann-Andersen1, K Krøyer Nielsen.   

Abstract

Ofloxacin belongs to a new generation of fluorinated quinolones which are structurally related to nalidixic acid. It is an orally or parenterally administered antibacterial drug active against most Gram-negative aerobic bacteria, many Gram-positive bacteria and some anaerobes. The pharmacokinetic profile or ofloxacin shows a rapid gastrointestinal absorption and high concentrations are achieved in most tissues and body fluids. Clinical efficacy of ofloxacin has been demonstrated in a variety of systemic infections as well as in acute and chronic urinary tract infections and ofloxacin has generally appeared to be at least as effective as comparative orally administered antibiotics. Ofloxacin is well tolerated and bacterial resistance does not appear to develop readily, however, noncritical use of quinolones in simple infections where standard drugs may be equally effective and safe should be discouraged. In conclusion, ofloxacin is an orally active drug which offers a valuable alternative to other broad spectrum antibacterial drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2218420

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  3 in total

1.  Sequential therapy with ofloxacin in complicated urinary tract infections: a randomized comparative study with ciprofloxacin.

Authors:  H J Peters
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.

Authors:  R Mattina; C E Cocuzza; M Cesana
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.